Figure 1 | Scientific Reports

Figure 1

From: Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9

Figure 1

Dinaciclib treatment and expression of CDK2/5/9 in CCA. (A) CHNG6, patient derived xenograft cells (PDXC) were subjected to a high throughput-drug screening and is significantly sensitive to dinaciclib at low nanomolar concentrations. (B) Relative mRNA expression of CDK2/5/9 are overexpressed in cholangiocarcinoma samples relative to normal samples from cBioportal database. mRNA expression was available for thirty-five tumor and ten normal samples. Expression of CDK’s was normalized with normal samples and the data presented as box plots. (C) Copy number analysis of thirty-five tumor samples from the cBioportal database indicates subsets of CCA samples with copy number gain in CDK2, CDK5 and CDK9. Copy number gain is presented in percentages.

Back to article page